Carboplatin and gemcitabine in the palliative treatment of stage IV non-small cell lung cancer: Definitive results of a phase II trial

Tumori

Volumn 90, Issue 1, 2004, Pages 54-59

  Tassinari, Davide ^a,c   Fochessati, Francesca ^a   Arcangeli, Valentina ^a   Sartori, Sergio ^b   Agostini, Vanessa ^a   Fantini, Manuela ^a   Genestreti, Giovenzio ^a   Grassia, Sergio ^a   Ioli, Giorgio ^a   Imola, Manuela ^a   Iorio, Domenico ^a   Mianulli, Anna Maria ^a   Monticelli, Giancarla ^a   Oliverio, Giovanni ^a   Panzini, Ilaria ^a   Papi, Maximilian ^a   Poggi, Barbara ^a   Polselli, Antonio ^a   Pulini, Stefano ^a   Tamburini, Emiliano ^a   Fattori, Pier Paolo ^a   Ravaioli, Alberto ^a   more..

^a City Hospital   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c NONE   (Italy)

Author keywords

Carboplatin; Gemcitabine; NSCLC; Palliative chemotherapy

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 11144353660     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000113     Document Type: Article

References (45)

1. Non Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ, 311: 899-909, 1995.
2. Crinò L, Cappuzzo F: Present and future treatment of advanced non-small cell lung cancer. Semin Oncol, 29 (Suppl): 9-16, 2002.
3. Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M: Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol, 17: 3522-3530, 1999.
4. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M: Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol, 20: 4285-4291, 2002.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 346: 92-98, 2002.
6. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol, 19: 3210-3218, 2001.
7. Ettinger DS: Is there a preferred combination chemotherapy regimen for metastatic non-small cell lung cancer? Oncologist, 7: 226-233, 2002.
8. Bonomi PA, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol, 7: 1602-1613, 1989.
9. Lokich J, Anderson N: Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol, 9: 13-21, 1998.
10. Thomas P, Robinet G, Ferri-Dessens RM, Lena H, Gouva S, Vernejoux JM, Kleisbauer JP: Phase I trial of gemcitabine and carboplatin in metastatic non-small cell lung cancer: a Groupe Francais de Pneumo-Cancerologie Study. Lung Cancer, 36: 191-198, 2002.
11. Gajra A, Mehdi SA, Kirshner J, Newman N, Graziano SL: Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma. Lung Cancer, 32: 189-196, 2002.
12. Carmichael J, Allerheiligen S, Walling J: A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol, 23 (5 suppl 10): 55-59, 1996.
13. Iaffaioli RV, Tortoriello A, Facchini G, Caponigro F, Gentile M, Marzano N, Gravina A, Dimitri P, Costagliola G, Ferraro A, Ferrante G, De Marino V, Illiano A: Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small cell lung cancer. J Clin Oncol, 17: 921-926, 1999.
14. Langer CJ, Gandara DR, Calvert P, Edelman MJ, Ozols RF: Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer. Semin Oncol, 26 (1 suppl 4): 12-18, 1999.
15. Tassinari D, Drudi G, Panzini I, Pasini G, Arcangeli V, Fochessati F, Gianni L, Mianulli AM, Oliverio G, Pasquini E, Sartori S, Ravaioli A: Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial. Int J Clin Oncol, 6: 279-283, 2001.
16. World Health Organization: Handbook for reporting results of cancer treatment. World Health Organization, Geneva, 1979.
17. National Cancer Institute Common Toxicity Criteria. Version 2.0, January 30, 1998. http://ctep.info.nih.gov/CTC3/ctc.htm.
18. Crinò L, Cappuzzo F: New platinum derivatives in advanced non-small cell lung cancer. Tumori, 88 (Suppl 4): S24-S25, 2002.
19. Monnet I, Brienza S, Hugret F, Voisin S, Gastiaburu J, Saltiel JC, Soulie P, Armand JP, Cvitkovic E, De Cremoux H: Phase II study of oxaliplatin in poor prognosis non-small cell lung cancer (NSCLC). Eur J Cancer, 14: 1124-1127, 1998.
20. Monnet I, Soulie P, De Cremoux H, Saltiel-Voisin S, Bekrada M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, Cvitkovic E: Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small cell lung cancer. J Clin Oncol, 19: 458-463, 2001.
21. Monnet I, De Cremoux H, Soulie P, Saltiel-Voisin S, Beckradda M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, Cvitkovic E: Oxaliplatin plus vinorelbine in advanced non-small cell lung cancer: final results of a multicenter phase II study. Ann Oncol, 13: 103-107, 2002.
22. Gandara D, Edelman MJ, Lara PN, Lau DH: Gemcitabine in combination with new platinum compounds: an update. Oncology, 15 (3 suppl 2): 1513-1517, 2001.
23. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berther P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G: Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol, 13: 1539-1549, 2002.
24. Richardet E, De La Collina M, Carranza L, Taddei E, Di Notto M, Espinosa F, Rodriguez S, Martinez L, Bertoncin A, Fernandez M, Bella S: Phase II study: weekly cisplatin (C) and gemcitabine (G) for stage IIIB-IV of NSCLC. Proc ASCO, 2711A, 2002.
25. Rudd RM, Gower NH, James LE, Gregory W, Eisen T, Lee SM, Harper PG, Spiro SG: Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc ASCO, 1164A, 2002.
26. Edelman MJ: Past, present and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer. Lung Cancer, 38: S37-S43, 2002.
27. Masotti A, Zannini G, Gentile A, Morandini G: Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial. Lung Cancer, 36: 99-103, 2002.
28. Sederholm C: Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin Oncol, 29 (3 suppl 9): 50-54, 2002.
29. Domine M, Casado V, Estevez LG, Leon A, Martin JI, Castillo M, Rubio G, Lobo F: Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer. Semin Oncol, 28 (3 suppl 10): 4-9, 2001.
30. Parente B, Barroso A, Conde S, Guimaraes T, Seada J: A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three- versus four-week schedule. Semin Oncol, 28 (3 suppl 10): 10-14, 2001.
31. Lenger CG, Gandara DR, Calvert P, Edelman MJ, Ozols RF: Gemcitabine and carboplatin in combination: an update of a phase I and phase II studies in non-small cell lung cancer. Semin Oncol, 26 (1 suppl 4): 12-18, 1999.
32. Gandara DR, Lau DH, Lara PN, Edelman MJ: Gemcitabine/carboplatin combination regimens: importance of dose schedule. Oncology, 14 (7 suppl 4): 26-30, 2000.
33. Ng EW, Sandler AB, Robinson L, Einhorn LH: A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a Hoosier Oncology Group study. Am J Clin Oncol, 22: 550-553, 1999.
34. Carrato A, Garcia-Gomez J, Alberola V, Massuti BJ, Sanchez J, Juan O, Diaz-Fernandez N, Galan A: Carboplatin (CARBO) in combination with gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC). Comparison of two consecutive phase II trials using different schedules. Proc ASCO, 1922 A, 1999.
35. Edelman MJ, Clark JI, Chansky K, Crowley J, Albain K, Gandara DR: Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine (CARB/G) followed by paclitaxel (P) or cisplatin/vinorelbine (C/V) followed by docetaxel (D). Proc ASCO, 1254A, 2001.
36. Jovtis S, Brocato N, Balbiani L, Temperly G, Zor A, Rondinon M, Almira E, Bruno M, Maldonado D, Cavarra G, Martinez J, Orlando M: First line therapy with gemcitabine (G) and carboplatin (C) in patients (pts) with advanced non-small cell lung cancer (NSCLC). A phase II study. Proc ASCO, 1969 A, 1999.
37. Maestu I, Torregosa MD, Llorca C: Carboplatin and gemcitabine in elderly patients with advanced non-small cell lung cancer. Preliminary results. Eur J Cancer, 35: 1040A, 1999.
38. Danson S, Clemons M, Middleton M: A randomized study of gemcitabine with carboplatin vs mitomycin, vinblastine and cisplatin or mitomycin, ifosfamide and cisplatin as first line chemotherapy in advanced non-small cell lung cancer. Proc ASCO, 1285A, 2001.
39. Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E: Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small cell lung cancer (NSCLC) stage III and IV: a phase III randomized trial. Lung Cancer, 37: 9-14, 2002.
40. Zatloukal P, Novakova L, Petruzelka L, Zemanova M, Kolck V, Grygarkova I, Sixtova D, Roubec J, Horenkova E, Kuta M, Havel L, Prusa P: Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small cell lung cancer (NSCLC): final results of Czech Lung Cancer Cooperative Group phase III randomized trial. Proc ASCO, 1225A, 2002.
41. Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer. A decade of progress. Chest, 122: 1037-1057, 2002.
42. Martins SJ, Pereira JR: Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol, 22: 453-460, 1999.
43. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small cell lung cancer. J Clin Oncol, 20: 1335-1343, 2002.
44. Smith IE, O'Brien MER, Talbot DC: Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol, 19: 1336-1343, 2001.
45. Socinski MA: Addressing the optimal duration of therapy in advanced, metastatic non-small cell lung cancer. ASCO 2003 Educational Book: 144-152, 2003.